弥散相关光谱无创颅内压监测的临床转化研究
本研究为前瞻性观察性研究,将基于弥散相关光谱(DCS)测量微血管脑血流(CBF)形态学分析的无创颅内压(ICP)估计方法转化至儿科患者,利用CBF特征联合平均动脉压(MAP)和心率(HR)构建随机决策森林机器学习模型,并与有创监测结果比较。共纳入15例患者,估计ICP与有创ICP高度吻合,在全部范围内均方根误差(RMSE)为1.01 mm Hg,95%一致性界限≤1.99 mm Hg。
要点
- DCS无创ICP估计与有创ICP高度吻合,全部范围内RMSE为1.01 mm Hg。
- CBF特征联合MAP和HR数据时预测准确度最佳。
- 留一法初步分析显示模型RMSE为6 mm Hg,一致性界限≤7 mm Hg。
核心结论
- DCS可能使ICP监测成为可能,但需进一步临床验证。
- 这种监测风险较低,可扩大ICP估计的适应症范围,从而减少有创监测器的使用并增加可能从ICP导向治疗中获益的患者类型。
研究设计与样本
- 前瞻性观察性研究,将临床前动物模型方法转化至儿科患者。
- 共纳入15例因任何原因接受有创神经监测的患者,平均年龄±标准差(范围)9.8±5.1(0.3-17.5)岁,中位年龄(四分位距)11(7.4)岁,男性10例、女性5例。
- 利用CBF特征联合MAP和HR数据构建随机决策森林机器学习模型估计ICP,并与有创监测结果比较。
主要发现
- 估计ICP与有创ICP高度吻合,在有创ICP 0.01-41.25 mm Hg范围内,RMSE为1.01 mm Hg,95%一致性界限≤1.99 mm Hg。
- 在有创ICP 0.01-29.05 mm Hg范围内,RMSE改善至0.81 mm Hg,一致性界限≤1.6 mm Hg。
- 在有创ICP≤20 mm Hg的测试样本中0.3%、>20 mm Hg的测试样本中5.4%的一致性界限>5 mm Hg;在较窄范围内,相应比例分别为0.1%和1.1%。
- CBF特征至关重要,但联合MAP和HR数据时预测准确度最佳。
- 留一法初步分析显示模型RMSE为6 mm Hg,一致性界限≤7 mm Hg。
局限性
- 原文结论指出DCS可能使ICP监测成为可能,但需进一步临床验证。
- 留一法分析为初步结果,模型RMSE为6 mm Hg,一致性界限≤7 mm Hg。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intracranial pressure (ICP) is an important therapeutic target in many critical neuropathologies. The current tools for ICP measurements are invasive; hence, these are only selectively applied in critical cases where the benefits surpass the risks. To address the need for low-risk ICP monitoring, the authors developed a noninvasive alternative. METHODS: The authors recently demonstrated noninvasive quantification of ICP in an animal model by using morphological analysis of microvascular cerebral blood flow (CBF) measured with diffuse correlation spectroscopy (DCS). The current prospective observational study expanded on this preclinical study by translating the method to pediatric patients. Here, the CBF features, along with mean arterial pressure (MAP) and heart rate (HR) data, were used to build a random decision forest, machine learning model for estimation of ICP; the results of this model were compared with those of invasive monitoring. RESULTS: Fifteen patients (mean age ± SD [range] 9.8 ± 5.1 [0.3-17.5] years; median age [interquartile range] 11 [7.4] years; 10 males and 5 females) who underwent invasive neuromonitoring for any purpose were enrolled. Estimated ICP (ICPest) very closely matched invasive ICP (ICPinv), with a root mean square error (RMSE) of 1.01 mm Hg and 95% limit of agreement of ≤ 1.99 mm Hg for ICPinv 0.01-41.25 mm Hg. When the ICP range (ICPinv 0.01-29.05 mm Hg) was narrowed on the basis of the sample population, both RMSE and limit of agreement improved to 0.81 mm Hg and ≤ 1.6 mm Hg, respectively. In addition, 0.3% of the test samples for ICPinv ≤ 20 mm Hg and 5.4% of the test samples for ICPinv > 20 mm Hg had a limit of agreement > 5 mm Hg, which may be considered the acceptable limit of agreement for clinical validity of ICP sensing. For the narrower case, 0.1% of test samples for ICPinv ≤ 20 mm Hg and 1.1% of the test samples for ICPinv > 20 mm Hg had a limit of agreement > 5 mm Hg. Although the CBF features were crucial, the best prediction accuracy was achieved when these features were combined with MAP and HR data. Lastly, preliminary leave-one-out analysis showed model accuracy with an RMSE of 6 mm Hg and limit of agreement of ≤ 7 mm Hg. CONCLUSIONS: The authors have shown that DCS may enable ICP monitoring with additional clinical validation. The lower risk of such monitoring would allow ICP to be estimated for a wide spectrum of indications, thereby both reducing the use of invasive monitors and increasing the types of patients who may benefit from ICP-directed therapies.
引用
- Tabassum S, Ruesch A, Acharya D, et al. Clinical translation of noninvasive intracranial pressure sensing with diffuse correlation spectroscopy. J Neurosurg. 2022. PMID: 36683191. doi:10.3171/2022.9.JNS221203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。